Ventyx Biosciences, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating expenses:
Research and development (includes related party amounts of $1,001 and $1,023, respectively)
General and administrative
Total operating expenses
Loss from operations
Other (income) expense:
Interest income
Other expense
Interest expense - related party
Change in fair value of notes and derivative - related party
Change in fair value of Series A tranche liability
Total other (income) expense

Net loss
Deemed dividend
Net loss attributable to common shareholders
Unrealized gain on marketable securities
Foreign currency translation
Comprehensive loss
Net loss per share attributable to common shareholders, basic and diluted
Shares used to compute basic and diluted net loss per share attributable to common shareholders
Net loss per share attributable to common shareholders, basic
Net loss per share attributable to common shareholders, diluted
Shares used to compute basic net loss per share attributable to common shareholders
Shares used to compute diluted net loss per share attributable to common shareholders

Comments